Journal of Diabetes and Its Complications
Volume 25, Issue 3 , Pages 151-158, May 2011

Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes☆☆☆

  • Fredrick L. Dunn

      Affiliations

    • University of Texas Southwestern Medical Center, Dallas, TX, USA
    • Corresponding Author InformationCorresponding author. Center for Human Nutrition, University of Texas Southwestern, Dallas, TX 75230-9052, USA.
    • ,
  • Linda S. Higgins

      Affiliations

    • InteKrin Therapeutics Inc., Los Altos, CA, USA
    • ,
  • Jill Fredrickson

      Affiliations

    • Pharsight Corporation, Mountain View, CA, USA
    • ,
  • Alex M. DePaoli

      Affiliations

    • InteKrin Therapeutics Inc., Los Altos, CA, USA
    • ,
  • for the INT131-004 study group

Received 17 March 2010; received in revised form 21 June 2010; accepted 30 June 2010. published online 26 August 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Clinical Trial Registration: NCT00952445.

☆☆ Disclosures: Dr. Dunn is a member of the Scientific Advisory Board of InteKrin Therapeutics Inc. Drs Higgins and DePaoli are employees of InteKrin Therapeutics. Dr. Fredrickson was previously employed by Pharsight.

PII: S1056-8727(10)00071-1

doi:10.1016/j.jdiacomp.2010.06.006

Journal of Diabetes and Its Complications
Volume 25, Issue 3 , Pages 151-158, May 2011

Article Tools

* Image Usage & Resolution